Improving the safety and continuity of medicines management at care transitions

Not Applicable

Completed

• Conditions: Heart failure; Circulatory System

• Registration Number: ISRCTN66212970
• Lead Sponsor: Bradford Teaching Hospitals NHS Foundation Trust

Brief Summary

2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/35487708/ (added 12/08/2022)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-04-11
• Study Completion: 2021-03-19
• Last Update Posted: 18 September 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 1641

Inclusion Criteria

1. Admitted or transferred to a ward participating in the ISCOMAT trial
2. Heart failure with evidence of at least moderate left ventricular systolic dysfunction confirmed (via echocardiogram) within the last 5 years
3. Aged 18 years or over at time of admission to hospital
4. Planned discharged from recruiting hospital to their home (defined by usual place of residence) or a care home
5. Planned discharge to within geographical area of that cluster
6. Capacity to provide Informed Consent
7. Provide informed consent

Exclusion Criteria

NHS Trusts meeting any of the following exclusion criteria will not be eligible for inclusion:
1. Already providing medicines management deemed to be sufficiently similar to the MaTI intervention

Patients meeting any of the following exclusion criteria will not be eligible for inclusion:
1. Patients in a terminal phase of illness / end of life care pathway who are not expected to survive beyond 6 weeks from date of discharge
2. Patients who are already participating in the ISCOMAT study (for example, patients who have been re-admitted)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
All-cause mortality and heart failure rehospitalisation; Timepoint(s): 12 months from discharge